Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Common Equity: 2023-2024

Historic Common Equity for Compass Therapeutics (CMPX) over the last 2 years, with Dec 2024 value amounting to $125.2 million.

  • Compass Therapeutics' Common Equity rose 51.46% to $209.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $209.6 million, marking a year-over-year increase of 51.46%. This contributed to the annual value of $125.2 million for FY2024, which is 15.69% down from last year.
  • As of FY2024, Compass Therapeutics' Common Equity stood at $125.2 million, which was down 15.69% from $148.5 million recorded in FY2023.
  • In the past 5 years, Compass Therapeutics' Common Equity registered a high of $148.5 million during FY2023, and its lowest value of $125.2 million during FY2024.
  • For the 2-year period, Compass Therapeutics' Common Equity averaged around $136.9 million, with its median value being $136.9 million (2023).
  • Data for Compass Therapeutics' Common Equity shows a maximum YoY decreased of 15.69% (in 2024) over the last 5 years.
  • Over the past 2 years, Compass Therapeutics' Common Equity (Yearly) stood at $148.5 million in 2023, then fell by 15.69% to $125.2 million in 2024.